Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a constant infusion rather than as a bolus dose. Forty-eight patients with advanced cancer received rIL-2 as a 24-hour infusion in five-day cycles separated by five-day periods of rest and leukapheresis. Eight patients were removed from the study before receiving cells activated in vitro. In the 40 who could be evaluated for their response, there were 13 partial responses (32.5 percent) and 2 minor responses. Partial responses were observed in Hodgkin's disease (one of one), non-Hodgkin's lymphoma (one of one), lung cancer (one of five), ovarian cancer (one of one), parotid cancer (one of two), renal cancer (three of six), and melanoma (five of ten). Responses were associated with a good performance status, a base-line lymphocyte count above 1400 per cubic millimeter, and an rIL-2-induced lymphocyte count of at least 6000. Optimal lymphocytosis required a priming dose of rIL-2 of 3 X 10(6) U per square meter of body-surface area per day, and 15 of 28 patients receiving this priming dose responded to treatment. A weight gain of more than 10 percent of total body weight (five patients) and dyspnea at rest (six patients) were unusual events restricted to patients with poorer pretreatment performance. We conclude that the administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
This article has been cited by other articles:
Parton, M., Gore, M., Eisen, T.
(2006). Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer. JCO
24: 5584-5592
[Abstract][Full Text]
Huang, J., Kerstann, K. W., Ahmadzadeh, M., Li, Y. F., El-Gamil, M., Rosenberg, S. A., Robbins, P. F.
(2006). Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy.. J. Immunol.
176: 7726-7735
[Abstract][Full Text]
Tourani, J.-M., Pfister, C., Tubiana, N., Ouldkaci, M., Prevot, G., Lucas, V., Oudard, S., Malet, M., Cottu, P., Ferrero, J.-M., Mayeur, D., Rixe, O., Sun, X.-S., Bernard, O., Andre, T., Tournigand, C., Muracciole, X., Guilhot, J.
(2003). Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group. JCO
21: 3987-3994
[Abstract][Full Text]
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., Matsumoto, Y.
(2002). Prognostic Significance of Adoptive Immunotherapy with Tumor-associated Lymphocytes in Patients with Advanced Gastric Cancer: A Randomized Trial. Clin. Cancer Res.
8: 1767-1771
[Abstract][Full Text]
Clark, J. I., Kuzel, T. M., Lestingi, T. M., Fisher, S. G., Sorokin, P., Martone, B., Viola, M., Sosman, J. A.
(2002). A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon {alpha}-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol
13: 606-613
[Abstract][Full Text]
Li, D., Shugert, E., Guo, M., Bishop, J. S., O'Malley, B. W. Jr
(2001). Combination Nonviral Interleukin 2 and Interleukin 12 Gene Therapy for Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg
127: 1319-1324
[Abstract][Full Text]
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., Rosenberg, S. A.
(2001). Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma. JCO
19: 3477-3482
[Abstract][Full Text]
Negrier, S., Caty, A., Lesimple, T., Douillard, J.-Y., Escudier, B., Rossi, J.-F., Viens, P., Gomez, F.
(2000). Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without Fluorouracil. JCO
18: 4009-4015
[Abstract][Full Text]
Pauline de La Salmonière, , Grob, J.-J., Dreno, B., Delaunay, M., Chastang, C.
(2000). White Blood Cell Count: A Prognostic Factor and Possible Subset Indicator of Optimal Treatment with Low-Dose Adjuvant Interferon in Primary Melanoma. Clin. Cancer Res.
6: 4713-4718
[Abstract][Full Text]
Dutcher, J. P., Logan, T., Gordon, M., Sosman, J., Weiss, G., Margolin, K., Plasse, T., Mier, J., Lotze, M., Clark, J., Atkins, M.
(2000). Phase II Trial of Interleukin 2, Interferon {{alpha}}, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study. Clin. Cancer Res.
6: 3442-3450
[Abstract][Full Text]
Kawamura, A. Jr, Sekine, T., Sekiguchi, M., Yanoma, S., Kaneko, A., Haneda, T., Moriya, Y., Hayasaka, K.-i., Kakizoe, T.
(2000). Six-year Disease-free Survival of a Patient with Metastatic Eyelid Squamous Cell Carcinoma and Colon Adenocarcinoma after Repeated Postoperative Adoptive Immunotherapy. Jpn J Clin Oncol
30: 267-271
[Abstract][Full Text]
Chen, S. A., Sawchuk, R. J., Brundage, R. C., Horvath, C., Mendenhall, H. V., Gunther, R. A., Braeckman, R. A.
(2000). Plasma and Lymph Pharmacokinetics of Recombinant Human Interleukin-2 and Polyethylene Glycol-Modified Interleukin-2 in Pigs. J. Pharmacol. Exp. Ther.
293: 248-259
[Abstract][Full Text]
de Gast, G. C., Klümpen, H.-J., Vyth-Dreese, F. A., Kersten, M.-J., Verra, N. C. V., Sein, J., Batchelor, D., Nooijen, W. J., Schornagel, J. H.
(2000). Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma. Clin. Cancer Res.
6: 1267-1272
[Abstract][Full Text]
Heinzer, H., Mir, T. S., Huland, E., Huland, H.
(1999). Subjective and Objective Prospective, Long-Term Analysis of Quality of Life During Inhaled Interleukin-2 Immunotherapy. JCO
17: 3612-3620
[Abstract][Full Text]
Escudier, B., Chevreau, C., Lasset, C., Douillard, J. Y., Ravaud, A., Fabbro, M., Caty, A., Rossi, J. F., Viens, P., Bergerat, J. P., Savary, J., Negrier, S.
(1999). Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?. JCO
17: 2039-2039
[Abstract][Full Text]
Li, D., Jiang, W., Bishop, J. S., Ralston, R., O'Malley, B. W. Jr.
(1999). Combination Surgery and Nonviral Interleukin 2 Gene Therapy for Head and Neck Cancer. Clin. Cancer Res.
5: 1551-1556
[Abstract][Full Text]
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T., The Groupe Francais d'Immunotherapie,
(1998). Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma. NEJM
338: 1272-1278
[Abstract][Full Text]
Kemeny, M. M., Botchkina, G. I., Ochani, M., Bianchi, M., Urmacher, C., Tracey, K. J.
(1998). The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc. Natl. Acad. Sci. USA
95: 4561-4566
[Abstract][Full Text]
O’Malley, B. W. Jr., Sewell, D. A., Li, D., Kosai, K.-i., Chen, S.-H., Woo, S. L.C., Duan, L.
(1997). The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer. Mol. Endocrinol.
11: 667-673
[Abstract][Full Text]
Ceballos, P. I., Ruiz-Maldonado, R., Mihm, M. C.
(1995). Melanoma in Children. NEJM
332: 656-662
[Full Text]
Takahashi, H, Nakada, T, Puisieux, I
(1993). Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science
259: 1460-1463
[Abstract]
Hanker, J., Giammara, B.
(1988). Biomaterials and biomedical devices. Science
242: 885-892
[Abstract]
Smith, K.
(1988). Interleukin-2: inception, impact, and implications. Science
240: 1169-1176
[Abstract]
Barnes, D.
(1987). Biologics gain influence in expanding NCI program. Science
237: 848-850
Previous
